BCL-2 (B-cell lymphoma 2) Inhibitor Market: By Product (Combination Therapy and Monotherapy), By Type (Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic leukemia, and Mantle Cell Lymphoma), and Geography

Purchase Option

$ 4400
$ 6600
$ 8900

BCL-2 (B-cell lymphoma 2) Inhibitor Market was valued at USD 1,657.8 million in 2022, growing at a 12.9% CAGR from 2023 to 2029. BCL-2 is a selective inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), with potential pro-apoptotic and antineoplastic activities. Upon administration, Bcl-2 inhibitor BCL201 binds to and inhibits the activity of Bcl-2. This restores apoptotic processes in tumor cells. With the rising prevalence of haematological cancer worldwide the demand for B-cell lymphoma 2 (Bcl-2) increased.

According to the leukemic & Lymphoma Society, approximately every 3 minutes, one person in the US is diagnosed with leukemia, lymphoma, or myeloma, an estimated combined total of 186,400 people in the US are expected to be diagnosed with leukemia, lymphoma, or myeloma in 2021, new cases of leukemia, lymphoma and myeloma are expected to account for 9.8 percent of the estimated 1,898,160 new cancer cases that will be diagnosed in the US in 2021, the large number from the journal shows high extensive for B-cell lymphoma 2 (Bcl-2) inhibitors which drives the market. The increasing population of geriatric patients worldwide has escalated the BCL-2 market; drugs reached a large stage of development gradually impacting on growth of the market consequences resulting in lucrative opportunities in the market. Pharmaceutical companies and research organizations are continuously growing on novel drug development, but government regulations and clinical trials approval hinder the market growth which become major restraints in the B-cell lymphoma 2 (Bcl-2) inhibitor market. Geographically, North America held the major market share in 2022 and is expected to dominate the global BCL-2 market in the forecasted years due to global key players in this region.

BCL-2 (B-cell lymphoma 2) Inhibitor Market Key Developments:
  • In June 2022, Ascentage Pharma Releases Encouraging Results of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Chinese Patients with Relapsed/Refractory Non-Hodgkin Lymphoma.
  • In April 2021, the U.S. Food and Drug Administration (FDA) announced the approval of BCMA-targeted CAR T-Cell Therapy for the treatment of blood cancer. The current approval is based in part on the findings of small research that found that idecabtagene vicleucel (ide-cel) reduced tumor size in 72 percent of patients. These effects persisted on average for 11 months.

BCL-2 Inhibitor Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

12.9%

Largest Market

North America

Fastest Growing Market

North America
BCL-2 Inhibitor Market Dynamics

The increasing prevalence of hematological diseases across the world is the major market driver in the BCL-2 Inhibitor Market during the forecast period. Blood cancer has become common among geriatric patients because it affects blood cells. Leukemia, lymphoma, and myeloma are some of the most common types of blood cancer. With the advanced development of novel drugs and continued approach towards health awareness in public about blood cancers, BCL-2 inhibitor drugs such as venetoclax and navitoclax selectively induce apoptosis in malignant cells reducing the risk factor, also increasing the demand for such drugs in the market which drives the market growth with significant growth.

Key Features of the Reports

  • The BCL-2 Inhibitor Market report provides granular level information about the market size, regional market share, historic market (2018-2022), and forecast (2023-2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies.
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market.
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market.
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenarios.

BCL-2 Inhibitor Market Segmentation

By Product Type
  • Combination Therapy
  • Monotherapy
By Type
  • Diffuse Large B-cell Lymphoma
  • Follicular Lymphoma
  • Chronic Lymphocytic leukemia
  • Mantle Cell Lymphoma
By Geography
  • North America
  • Europe
  • The Asia Pacific
  • Latin America
  • MEA

Frequently Asked Questions

The BCL-2 Inhibitor Market size was valued at USD 1,657.8 million in 2022.

The BCL-2 Inhibitor Market is poised to grow at a significant CAGR of 12.9% from 2022 to 2028.

The leading players in the BCL-2 Inhibitor Market are Abcam plc, Amgen Inc., Novartis AG, Santa Cruz Biotechnology Inc., Seagen Inc., Servie, Biorbyt Ltd., Ascentage Pharma Group International, AstraZeneca Plc, BeiGene Ltd., Bio-Techne Corp., Biorbyt Ltd., Bristol Myers Squibb Co., F. Hoffmann La Roche Ltd., Ipsen Pharma, and Merck & Co. Inc.

  • Abcam plc
  • Amgen Inc.
  • Novartis AG
  • Santa Cruz Biotechnology Inc.
  • Seagen Inc.
  • Servie
  • Biorbyt Ltd.
  • Ascentage Pharma Group International
  • AstraZeneca Plc
  • BeiGene Ltd.
  • Bio Techne Corp.
  • Biorbyt Ltd.
  • Bristol Myers Squibb Co.
  • Hoffmann La Roche Ltd.
  • Ipsen Pharma
  • Merck and Co. Inc.

Adjacent Markets